G. Martin, A. Wolf., P. Rabinovich, M. Meyeroff
NOTA Laboratories LLC, United States
Keywords: nitric oxide (NO), iNO device, S-nitrosothiols (RSNO), traumatic brain injury (TBI), therapeuticNitric oxide (NO), a vasodilator, is a key regulator of cerebral blood flow (CBF) acting via both autoregulation and neurovascular coupling mechanisms. NO also exhibits anti-inflammatory and anti-platelet activity which are likely important in protecting brain tissue after injury. Endothelial NO (eNO) is critical to CBF regulation and it has been shown that eNO synthesis and metabolism are greatly disrupted by brain injury, e.g. trauma, ischemic stroke. It has also been demonstrated that many of traumatic brain injury (TBI) effects are related to the extent of eNO depression. Recently, it has been shown that inhaled NO (iNO) therapy, if begun within 1 hr of brain injury and provided continuously, is neuroprotective and mitigates secondary brain damage. To meet the need to initiate iNO therapy quickly after a potential TBI NOTA proposes to develop a face mask device that relies upon moisture activated controlled release of NO gas from specially formulated tablets containing S-nitrosothiol (RSNO), a stable form of NO when kept dry. The mask once affixed to the face will spontaneously generate NO when activated by either the patient’s own exhaled breath or by pre-humidified air pumped into the mask.